Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by SABBOBCATon Oct 18, 2019 3:16pm

84 Views

Post# 30245205

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I just need one question answered

AASLD - The Liver MEeting matches those dates, but I havent been able to find any info on him presenting so far.

SPCEO1 wrote: I am not sure the name of the conference but I have been told it will be held from 11/8 - 12

jfm1330 wrote: If I remember well, on top of R&D day next week, Grinspoon was supposed to present his results at a scientific conference somewhere. Do we know where and when?